Abstract
Immunotherapy represents one of the approaches for the treatment of cancer. Compounds which are able to act as toll-like receptors (TLRs) agonists may represent promising candidates to be developed as medicines cancer. The high rates of non muscle invasive bladder cancer (NMIBC) recurrence may be related to low effects of these therapies on the mechanisms of tissue repair, involving TLRs …